![]() ![]() Ocrevus is given as an intravenous infusion every six months. The OCREVUS Co-pay Program offers both drug and administration co-pay support for OCREVUS. Call (844) OCREVUS (844) 627-3887 to speak to a Patient Navigator or visit to learn more. Kesimpta is self-injected under the skin once monthly. If a patient is not eligible for the OCREVUS Co-pay Program, there may be other options for co-pay assistance. Then try and schedule your treatment as soon after your insurance coverage starts so you can see what the cost after insurance is for you. The main differentiation between the two drugs is the delivery system and the annual cost of therapy, which is $65,000 for Ocrevus compared to $83,000 for Kesimpta in the US." Basically (US based) if you are in the ocrevus copay program (your Dr can generally help or get a pharmacist to help set that up) make sure your insurance will cover ocrevus after you meet your deductible. That’s not high compared to some other MS drugs, but it still can mean a higher co-pay than some patients with insurance can afford. "The safety and efficacy data of Ocrevus is, overall, comparable with that of Kesimpta. Co-Pay Program . Ocrevus carries a price tag of about 65,000 a year.– Novartis' Kesimpta to compete with Roche's Ocrevus in MS: ![]() Welcome, I'm tagging other members who live with multiple sclerosis, like to see if they have experience with either Ocrevus or Kesimpta.Īccording to a clinical trial comparing Kesimpta (ofatumumab) to Ocrevus for the treatment of relapsing forms of multiple sclerosis (RMS) in adults, the main difference is cost and how the drug is administered. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |